: iStockAnalyst.com Symbols Feed

Healthcare M&A Activitiy: Three Healthcare Small Caps Primed For Takeovers

Thu, 22 Oct 2009 16:22:43 GMT

With the healthcare debate still raging in Washington, this should shock you… Healthcare mergers and acquisition (M&A) activity is at an all-time high.[More...]

Is It The Right Time To Buy Biotechnology Investments?

Thu, 30 Jul 2009 19:39:43 GMT

Share prices in the biotech sector have seen strong gains in recent weeks and it is logical to ask if it is too late to get on the biotech bandwagon. The answer, generally speaking, is no as long as investors get a few things right.[More...]

FDA Calendar Updates: BVX, HEB, HGSI, ONXX, SGP, ARDM, CBRX, MDT, Takeda

Thu, 23 Jul 2009 15:48:00 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 273 entries as of 7/22/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete respo (...)[More...]

Biotech Industry Overview

Mon, 01 Jun 2009 14:38:59 GMT

The Biotech industry as a whole continues to underperform the market so far this year. As of May 26, 2009, Both the AMEX Biotech Index and the broader NASDAQ Biotech Index declined 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index inc[More...]

Biotech Industry - Industry Outlook

Thu, 16 Apr 2009 20:54:01 GMT

Last year, the Biotech industry as a whole achieved a much better performance than the market. Both the NASDAQ Biotech Index and AMEX Biotech Index outperformed all three major market indices (Dow Jones Industrial Average, NASDAQ Composite and S&P 500) in a large margin. The major indices declined as much as 40% while the NASDAQ Biotech Index declined only 12.6% and the AMEX Biotech Index was down 17.7%. However, when the recession enters into its third year, the Biotech industry is not doing better than the market, which has been evident by the indices' performances. As of April 9, 2009, AMEX Biotech Index declined 3%, and the broader NASDAQ Biotech Index was down 6.8% (AMEX Biotech has 20 biotech companies while NASDAQ Biotech Index includes over 130 component companies). Although the Dow and S&P 500 also declined a similar percentage, technology-laden NASDAQ actually has a gain of 4.8%, which is more comparable to the biotech indices. See[More...]

Biotechnology Industry - Zacks Analyst Interviews

Fri, 05 Dec 2008 12:44:00 GMT

Historically, the biotech industry was less impacted by market conditions due to its unique characteristics. In large part, biotech stocks have been event-driven. Specifically, investors are more focused on clinical development and pipeline advancement for individual biotech companies. However, current market conditions have exerted a negative impact on the valuation of individual companies in the biotech industry. We believe the different impact current market conditions have exerted is mainly due to the credit crunch. Most biotech companies are in early or middle development stages, and continuing financing is an integral part of their operations in order to advance their drug pipelines. Under current market conditions, liquidity has dried up for some companies, and raising capital has been extremely difficult in the past few months. Some companies are forced to enter into survival mode to reserve cash by restructuring. Some even have to suspend operations[More...]

Biotechnology Industry

Thu, 04 Dec 2008 20:05:00 GMT

Historically, the biotech industry has been less impacted by market conditions due to its unique characteristics. In large part, biotech stocks have been event-driven. Specifically, investors are more focused on clinical development and pipeline advancement for individual biotech companies. ? However, current market conditions have exerted a negative impact on the valuation of individual companies in the biotech industry. We believe the different impact current market conditions have exerted is mainly due to the credit crunch. Most biotech companies are in early or middle development stages, and continuing financing is an integral part of their operations in order to advance their drug pipelines. Under current market conditions, liquidity has dried up for some companies, and raising capital has been extremely difficult in the past few months. Some companies are forced to enter into survival mode to reserve cash by[More...]

Pharmaceuticals Industry

Fri, 21 Nov 2008 20:17:00 GMT

Names that were previously viewed as safe and stable investments, large-cap pharmaceuticals, are now trading at levels not seen since 2002.? And, for some such as Pfizer, Inc. (PFE) and Eli Lilly & Co. (LLY), these are prices not seen since the past decade. This is clearly a sell-first, ask questions later market. After all, believing that patients are going to stop taking Bristol-Myers Squibb Co. (BMY) blood-thinner Plavix or Pfizer's anti-cholesterol agent Lipitor because of the credit crunch is the epitome of irrational anxiety. [More...]

Onyx Pharma Bullish on Nexavar - Analyst Blog

Wed, 22 Oct 2008 18:26:00 GMT

Onyx Pharma (ONXX) is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its collaborator Bayer Healthcare,?Onyx Pharma?is developing a small molecule drug Nexavar (sorafenib). The European Union (EU) and U.S. have approved Nexavar for 1st line treatment of liver cancer in the 4th quarter of 2007. In Asia, South Korea and China have approved Nexavar for liver cancer. We believe Nexavar sales will be further boosted in the rest of 2008 and beyond due to this new indication. Label expansion for Nexavar into other cancer indications such as breast cancer is underway. We believe Nexavar has a potential to become a blockbuster for Onyx Pharma. We model sales of Nexavar will reach $.1 billion in 2010. [More...]

Onyx Pharma - Bullish on Nexavar - Analyst Blog

Wed, 22 Oct 2008 16:03:00 GMT

KB Home, AMD, Black & Decker big movers

Mon, 12 Oct 2009 20:47:00 GMT

NEW YORK - The following stocks were among those that moved substantially or traded heavily Monday on the New York Stock Exchange:
Advanced Micro Devices Inc., up 26 cents at $6.14
A UBS analyst upgraded the stock to "Buy" and raised his target price and earnings estimates due to expectations for increased growth.

: iStockAnalyst.com Symbols Feed

Healthcare M&A Activitiy: Three Healthcare Small Caps Primed For Takeovers

Is It The Right Time To Buy Biotechnology Investments?

FDA Calendar Updates: BVX, HEB, HGSI, ONXX, SGP, ARDM, CBRX, MDT, Takeda

Biotech Industry Overview

Biotech Industry - Industry Outlook

Biotechnology Industry - Zacks Analyst Interviews

Biotechnology Industry

Pharmaceuticals Industry

Onyx Pharma Bullish on Nexavar - Analyst Blog

Onyx Pharma - Bullish on Nexavar - Analyst Blog

KB Home, AMD, Black & Decker big movers

Onyx Reports Turnaround in Year-End Results

RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on MGM, MDT, MO, MENT, ONXX and WFMI

Biotech Cools Off in August But Capital Markets Remain Positive

Biotech Cools Off in August But Capital Markets Remain Positive

Onyx Pharmaceuticals Announces Pricing of Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes

Onyx Pharmaceuticals to Present at the 29th Annual Canaccord Adams Global Growth Conference

Onyx Pharmaceuticals Announces Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes

Onyx Pharmaceuticals Announces Concurrent Offerings of Four Million Shares of Common Stock and $200 Million Principal Amount of Convertible Senior Notes

Onyx Pharmaceuticals Reports Second Quarter 2009 Financial Results; Nexavar Global Net Sales Reach $201 Million, 19% Increase Over Second Quarter 2008

Onyx Pharmaceuticals Announces Second Quarter 2009 Financial Results Teleconference and Webcast

StockPreacher.com Issues Trading Outlook for Onyx Pharmaceuticals Inc. (ONXX)

Form 4 SHEMA SUZANNE M For: Aug 31 (10K)

Form 3 SHEMA SUZANNE M For: Aug 31 (10K)

Form 4 Lasowski Juergen For: Aug 14 (10K)

Form 4 Lasowski Juergen For: Jul 22 (10K)

Form 4 WOOD JULIANNA R For: Jul 22 (10K)

Form 4 Brege Laura For: Jul 22 (10K)

Form 4 Lasowski Juergen For: Jun 26 (10K)

Form 4 Lasowski Juergen For: May 20 (10K)

Form 4 COLES N ANTHONY For: Apr 06 (10K)

Form 4 ONYX PHARMACEUTICALS For: Mar 31 Filed by: WIERENGA WENDALL (10K)